Feuerstein T J, Hertting G, Lupp A, Neufang B
Br J Pharmacol. 1986 Jul;88(3):677-84. doi: 10.1111/j.1476-5381.1986.tb10250.x.
The effect of the catecholamine uptake inhibitor nomifensine and of the 5-hydroxytryptamine (5-HT) uptake blocker 6-nitroquipazine on the accumulation of [3H]-5-HT (0.1 microM, 60 min incubation) and [3H]-dopamine (0.1 microM, 30 min incubation) into slices of hippocampus and caudate nucleus of the rabbit was investigated. In addition, the influence of nomifensine on the electrically evoked [3H]-5-HT release from caudate nucleus slices and of nomifensine and 6-nitroquipazine on [3H]-5-HT released from caudate nucleus slices was analysed. In hippocampal slices, which contain practically no dopaminergic but densely distributed 5-hydroxytryptaminergic and noradrenergic nerve terminals (ratio of dopamine:5-HT:noradrenaline about 1:30:25), nomifensine (1, 10 microM) did not affect the accumulation of [3H]-5-HT; 6-nitroquipazine (1 microM) reduced [3H]-5-HT uptake to about 35% of controls. In the caudate nucleus, however, where dopamine is the predominant monoamine (ratio of dopamine:5-HT:noradrenaline about 400:25:15) nomifensine (1, 10 microM) reduced the tritium accumulation to 65% whereas 6-nitroquipazine (1 microM) was ineffective. The combination of both drugs (1 microM each) led to a further decrease to about 15%. The uptake of [3H]-dopamine into hippocampal slices was blocked by both nomifensine (1 microM) and 6-nitroquipazine (1 microM) whereas in caudate nucleus slices only nomifensine (1, 10 microM) reduced the accumulation of [3H]-dopamine. The combination of both drugs was not more effective than nomifensine alone. The different effects of both uptake inhibitors in the hippocampus and caudate nucleus suggest a neurone specific rather than a substrate specific mode of action. 4 In caudate nucleus slices incubated with [3H]-5-HT and superfused continuously the electrically evoked 5-HT release was diminished by the D2-dopamine receptor agonist LY 171555 and enhanced by the D2-receptor antagonist domperidone. If, however, the labelling of caudate nucleus slices was performed in the presence of I microM or 1O microM nomifensine, the modulation of 5-HT release via D2- receptors was reduced or abolished, respectively. In the hippocampus both LY 171555 and domperidone were completely ineffective in modulating 5-HT release regardless of the absence or presence of nomifensine. 5 The present results indicate that an inverse cross labelling of [3H]-5-HT into dopaminergic and of [3H]-dopamine into 5-hydroxytryptaminergic terminals may occur despite the low concentration (0.1 microM) oftritiated transmitters used. Such cross labelling, as demonstrated with the incubation period of 60 min in the caudate nucleus, may falsely indicate the existence of D2-dopamine receptors modulating [3H]-5-HT release. If both 5-hydroxytryptaminergic and dopaminergic terminals are present within the brain region under investigation false labelling can be corrected using neuronally specific uptake inhibitors.
研究了儿茶酚胺摄取抑制剂诺米芬辛和5-羟色胺(5-HT)摄取阻滞剂6-硝基喹哌嗪对[3H]-5-HT(0.1微摩尔,孵育60分钟)和[3H]-多巴胺(0.1微摩尔,孵育30分钟)在兔海马和尾状核切片中蓄积的影响。此外,分析了诺米芬辛对尾状核切片中电诱发的[3H]-5-HT释放的影响,以及诺米芬辛和6-硝基喹哌嗪对尾状核切片中[3H]-5-HT释放的影响。在海马切片中,几乎不含多巴胺能神经末梢,但5-羟色胺能和去甲肾上腺素能神经末梢分布密集(多巴胺:5-HT:去甲肾上腺素的比例约为1:30:25),诺米芬辛(1、10微摩尔)不影响[3H]-5-HT的蓄积;6-硝基喹哌嗪(1微摩尔)将[3H]-5-HT摄取降低至对照的约35%。然而,在尾状核中,多巴胺是主要的单胺(多巴胺:5-HT:去甲肾上腺素的比例约为400:25:15),诺米芬辛(1、10微摩尔)将氚蓄积降低至65%,而6-硝基喹哌嗪(1微摩尔)无效。两种药物(各1微摩尔)联合使用导致进一步降低至约15%。诺米芬辛(1微摩尔)和6-硝基喹哌嗪(1微摩尔)均阻断[3H]-多巴胺进入海马切片的摄取,而在尾状核切片中只有诺米芬辛(1、10微摩尔)降低[3H]-多巴胺的蓄积。两种药物联合使用并不比单独使用诺米芬辛更有效。两种摄取抑制剂在海马和尾状核中的不同作用表明其作用方式具有神经元特异性而非底物特异性。4 在与[3H]-5-HT孵育并持续灌流的尾状核切片中,D2-多巴胺受体激动剂LY 171555可减少电诱发的5-HT释放,D2-受体拮抗剂多潘立酮则可增强该释放。然而,如果在1微摩尔或10微摩尔诺米芬辛存在的情况下对尾状核切片进行标记,则通过D2-受体对5-HT释放的调节分别降低或消除。在海马中,无论是否存在诺米芬辛,LY 171555和多潘立酮在调节5-HT释放方面均完全无效。5 目前的结果表明,尽管使用的氚标记递质浓度较低(0.1微摩尔),但[3H]-5-HT可能反向交叉标记到多巴胺能末梢,[3H]-多巴胺可能反向交叉标记到5-羟色胺能末梢。如在尾状核中60分钟孵育期所证明的那样,这种交叉标记可能错误地表明存在调节[3H]-5-HT释放的D2-多巴胺受体。如果在所研究的脑区中同时存在5-羟色胺能和多巴胺能末梢,则可使用神经元特异性摄取抑制剂来纠正错误标记。